Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M. Marcinek A, et al. Among authors: kobold s. Cancer Immunol Immunother. 2023 Jul;72(7):2499-2512. doi: 10.1007/s00262-023-03439-x. Epub 2023 Apr 11. Cancer Immunol Immunother. 2023. PMID: 37041225 Free PMC article.
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M. Marcinek A, et al. Among authors: kobold s. Cancer Immunol Immunother. 2023 Jul;72(7):2513-2514. doi: 10.1007/s00262-023-03457-9. Cancer Immunol Immunother. 2023. PMID: 37154851 Free PMC article. No abstract available.
Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming.
Wu H, Zhao X, Hochrein SM, Eckstein M, Gubert GF, Knöpper K, Mansilla AM, Öner A, Doucet-Ladevèze R, Schmitz W, Ghesquière B, Theurich S, Dudek J, Gasteiger G, Zernecke A, Kobold S, Kastenmüller W, Vaeth M. Wu H, et al. Among authors: kobold s. Nat Commun. 2023 Oct 27;14(1):6858. doi: 10.1038/s41467-023-42634-3. Nat Commun. 2023. PMID: 37891230 Free PMC article.
Migratory Engineering of T Cells for Cancer Therapy.
Michaelides S, Obeck H, Kechur D, Endres S, Kobold S. Michaelides S, et al. Among authors: kobold s. Vaccines (Basel). 2022 Oct 31;10(11):1845. doi: 10.3390/vaccines10111845. Vaccines (Basel). 2022. PMID: 36366354 Free PMC article. Review.
CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NU, Wogsland C, Gjerstad ME, Fløisand Y, Kvalheim G, Marr C, Kobold S, Enserink JM, Gjertsen BT, McCormack E, Inderberg EM, Wälchli S. Caulier B, et al. Among authors: kobold s. Cell Rep Med. 2024 Jun 18;5(6):101572. doi: 10.1016/j.xcrm.2024.101572. Epub 2024 May 15. Cell Rep Med. 2024. PMID: 38754420 Free PMC article.
Multiomic analyses uncover immunological signatures in acute and chronic coronary syndromes.
Pekayvaz K, Losert C, Knottenberg V, Gold C, van Blokland IV, Oelen R, Groot HE, Benjamins JW, Brambs S, Kaiser R, Gottschlich A, Hoffmann GV, Eivers L, Martinez-Navarro A, Bruns N, Stiller S, Akgöl S, Yue K, Polewka V, Escaig R, Joppich M, Janjic A, Popp O, Kobold S, Petzold T, Zimmer R, Enard W, Saar K, Mertins P, Huebner N, van der Harst P, Franke LH, van der Wijst MGP, Massberg S, Heinig M, Nicolai L, Stark K. Pekayvaz K, et al. Among authors: kobold s. Nat Med. 2024 Jun;30(6):1696-1710. doi: 10.1038/s41591-024-02953-4. Epub 2024 May 21. Nat Med. 2024. PMID: 38773340 Free PMC article.
HDR-based CRISPR/Cas9-mediated Knockout of PD-L1 in C57BL/6 Mice.
Heeb LV, Taskoparan B, Katsoulas A, Beffinger M, Clavien PA, Kobold S, Gupta A, Berg JV. Heeb LV, et al. Among authors: kobold s. Bio Protoc. 2023 Jul 20;13(14):e4724. doi: 10.21769/BioProtoc.4724. eCollection 2023 Jul 20. Bio Protoc. 2023. PMID: 37497456 Free PMC article.
Programmable multispecific DNA-origami-based T-cell engagers.
Wagenbauer KF, Pham N, Gottschlich A, Kick B, Kozina V, Frank C, Trninic D, Stömmer P, Grünmeier R, Carlini E, Tsiverioti CA, Kobold S, Funke JJ, Dietz H. Wagenbauer KF, et al. Among authors: kobold s. Nat Nanotechnol. 2023 Nov;18(11):1319-1326. doi: 10.1038/s41565-023-01471-7. Epub 2023 Aug 17. Nat Nanotechnol. 2023. PMID: 37591933 Free PMC article.
9th Immunotherapy of Cancer conference (ITOC): A meeting report.
Dalloul I, Strzalkowski TJC, von Bergwelt-Baildon M, Nüssler V, Zielinski C, Kobold S. Dalloul I, et al. Among authors: kobold s. Hum Vaccin Immunother. 2022 Dec 30;18(7):2159706. doi: 10.1080/21645515.2022.2159706. Epub 2022 Dec 28. Hum Vaccin Immunother. 2022. PMID: 36576266 Free PMC article.
156 results